Histologic and molecular analysis of patient derived xenografts of high-grade serous ovarian carcinoma

BackgroundPatient derived xenografts (PDX) are generated by transplanting the original patient’s tumor tissue into immune-deficient mice. Unlike xenograft models derived from cell lines, PDX models can better preserve the histopathology from the original patient and molecular pathways. High-grade serous carcinoma (HGSC) is a deadly form of ovarian/fallopian tube cancer whose response to current chemotherapies varies widely due to patient variability. Therefore, a PDX model can provide a valuable tool to study and test treatment options for each individual patient.MethodsIn this study, over 200 PDX tumors from nine HGSC were analyzed to investigate the nature and behavior of PDX tumors originating from HGSC. PDX tumors were serially passaged (from P0 to P4) and tumors were grafted orthotopically under the ovarian bursa or subcutaneously.ResultsComparative analysis of the histology and molecular markers of tumors from over 200 PDX tumor-bearing mice, revealed that the tumors maintained similar histologies, stem cell populations, and expression for the majority of the tested oncogenic markers, compared to the primary tumors. However, a significant loss of steroid hormone receptors and altered expression of immunoresponsive genes in PDX tumors were also noted. ConclusionOur findings provide substantial new information about PDX tumor characteristics from HGSC which will be valuable towards the development of personalized therapy and new drug development for HGSC.

[1]  R. J. Kelleher,et al.  Humanized Mouse Model of Ovarian Cancer Recapitulates Patient Solid Tumor Progression, Ascites Formation, and Metastasis , 2011, PloS one.

[2]  Alessandro De Luca,et al.  Xenografts of primary human gynecological tumors grown under the renal capsule of NOD/SCID mice show genetic stability during serial transplantation and respond to cytotoxic chemotherapy. , 2008, Gynecologic oncology.

[3]  D. Huntsman,et al.  Establishment of subrenal capsule xenografts of primary human ovarian tumors in SCID mice: potential models. , 2005, Gynecologic oncology.

[4]  Manuel Hidalgo,et al.  Patient-derived xenograft models: an emerging platform for translational cancer research. , 2014, Cancer discovery.

[5]  S. Orsulic,et al.  Ovarian Cancer , 1993, British Journal of Cancer.

[6]  W. Kleine.  Prognostic significance of growth characteristics of xenotransplanted ovarian carcinomas into nude mice. , 1986, Gynecologic oncology.

[7]  Joshua M. Korn,et al.  High-throughput screening using patient-derived tumor xenografts to predict clinical trial drug response , 2015, Nature Medicine.

[8]  B. Rueda,et al.  Inhibition of Notch Signaling in Combination with Paclitaxel Reduces Platinum-Resistant Ovarian Tumor Growth , 2014, Front. Oncol..

[9]  F. Balkwill,et al.  Intraperitoneal xenografts of human epithelial ovarian cancer in nude mice. , 1987, Cancer research.

[10]  C. Scott,et al.  Patient-Derived Xenograft Models to Improve Targeted Therapy in Epithelial Ovarian Cancer Treatment , 2013, Front. Oncol..

[11]  Jeong-Won Lee,et al.  Sphingosine kinase 1 as a potential therapeutic target in epithelial ovarian cancer , 2015, International journal of cancer.

[12]  D. Bowtell,et al.  Identification of Novel Therapeutic Targets in Microdissected Clear Cell Ovarian Cancers , 2011, PloS one.

[13]  D. Roberts,et al.  CD133 Expression Defines a Tumor Initiating Cell Population in Primary Human Ovarian Cancer , 2009, Stem cells.

[14]  M. Piver,et al.  Characterization of human ovarian carcinomas in a SCID mouse model. , 1999, Gynecologic oncology.

[15]  B. Neel,et al.  Phenotypic heterogeneity and instability of human ovarian tumor-initiating cells , 2011, Proceedings of the National Academy of Sciences.

[16]  B. Hylander,et al.  Recombinant CD40 ligand therapy has significant antitumor effects on CD40-positive ovarian tumor xenografts grown in SCID mice and demonstrates an augmented effect with cisplatin. , 2001, Cancer research.

[17]  Zhaojian Liu,et al.  Anti-miR182 Reduces Ovarian Cancer Burden, Invasion, and Metastasis: An In Vivo Study in Orthotopic Xenografts of Nude Mice , 2014, Molecular Cancer Therapeutics.

[18]  Michael J. Birrer,et al.  Inhibition of Hedgehog Signaling Antagonizes Serous Ovarian Cancer Growth in a Primary Xenograft Model , 2011, PloS one.

[19]  P. Allavena,et al.  Intraperitoneal and subcutaneous xenografts of human ovarian carcinoma in nude mice and their potential in experimental therapy , 1989, International journal of cancer.

[20]  P. Scheffer,et al.  Development of a panel of 15 human ovarian cancer xenografts for drug screening and determination of the role of the glutathione detoxification system. , 2000, Gynecologic oncology.

[21]  R. Hoffman,et al.  Human ovarian carcinoma metastatic models constructed in nude mice by orthotopic transplantation of histologically-intact patient specimens. , 1993, Anticancer research.

[22]  Zachary C. Dobbin,et al.  Using heterogeneity of the patient-derived xenograft model to identify the chemoresistant population in ovarian cancer , 2014, Oncotarget.

[23]  P. Ostano,et al.  Patient-derived ovarian tumor xenografts recapitulate human clinicopathology and genetic alterations. , 2014, Cancer research.

[24]  I. Fidler,et al.  Murine models to evaluate novel and conventional therapeutic strategies for cancer. , 2007, The American journal of pathology.

[25]  G. Hannon,et al.  Patient-derived tumor xenografts: transforming clinical samples into mouse models. , 2013, Cancer research.

[26]  J. V. Johannessen,et al.  Heterologous Growth of Human Ovarian Cancer: A New in Vivo Testing System , 1977, Acta obstetricia et gynecologica Scandinavica.

[27]  S. Fox,et al.  Molecular correlates of platinum response in human high‐grade serous ovarian cancer patient‐derived xenografts , 2014, Molecular oncology.

[28]  M. Hidalgo,et al.  Direct In Vivo Xenograft Tumor Model for Predicting Chemotherapeutic Drug Response in Cancer Patients , 2009, Clinical pharmacology and therapeutics.

[29]  H. Mackay,et al.  Patient-derived xenograft models in gynecologic malignancies. , 2014, American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting.

[30]  R. Bast,et al.  Establishment and characterization of cancer cell cultures and xenografts derived from primary or metastatic Mullerian cancers. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[31]  Haiyang Guo,et al.  Molecular analyses of 6 different types of uterine smooth muscle tumors: Emphasis in atypical leiomyoma , 2014, Cancer.

[33]  S. Bapat,et al.  Stem and progenitor-like cells contribute to the aggressive behavior of human epithelial ovarian cancer. , 2005, Cancer research.

[34]  N. Dubrawsky.  Cancer statistics , 1989, CA: a cancer journal for clinicians.

[35]  M. Esteller,et al.  Lurbinectedin (PM01183), a New DNA Minor Groove Binder, Inhibits Growth of Orthotopic Primary Graft of Cisplatin-Resistant Epithelial Ovarian Cancer , 2012, Clinical Cancer Research.

[36]  G. Ning,et al.  Through the glass darkly: intraepithelial neoplasia, top‐down differentiation, and the road to ovarian cancer , 2013, The Journal of pathology.

[37]  Emanuela M. Ghia,et al.  Ovarian cancer stem cells express ROR1, which can be targeted for anti–cancer-stem-cell therapy , 2014, Proceedings of the National Academy of Sciences.

[38]  A. Jemal,et al.  Cancer statistics, 2014 , 2014, CA: a cancer journal for clinicians.

[39]  R. L. Baldwin,et al.  A human ovarian carcinoma murine xenograft model useful for preclinical trials. , 2002, Gynecologic oncology.

[40]  S. Nicosia,et al.  One mouse, one patient paradigm: New avatars of personalized cancer therapy. , 2014, Cancer letters.

[41]  J. Sarkaria,et al.  Tumorgrafts as In Vivo Surrogates for Women with Ovarian Cancer , 2014, Clinical Cancer Research.

[42]  Jian-Jun Wei,et al.  miR-145 inhibits tumor growth and metastasis by targeting metadherin in high-grade serous ovarian carcinoma , 2014, Oncotarget.